Many of the effects of TTA in this study point in direction of PPARα as well as PPARδ activation, with a similar pattern of lipid lowering effects as observed in patients with impaired glucose tolerance after treatment with fenofibrate, which is a selective PPARα agonist [1, 5]. The gene discussed is PPARA; the disease is Impaired glucose tolerance.